The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available ... All problems (adverse events) related to a medicine or medical ...
on teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) and submitted it to NICE. The FDG has been sent to consultees for this appraisal who ...